Abstract
To evaluate ability of modulated innate immune response to provide resistance to development of symptomatic RT-PCR confirmed COVID-19, 96 inpatient front line health care workers (HCW) were cohorted in 1:2 ratio to receive TLR2 agonist (heat killed Mycobacterium w, Mw; n=32) as innate immune response modulator or observation (n=64). All were followed up for 100 days. The incidence of COVID-19 was 31 (32.3%) for the entire cohort, with only one developing COVID-19 in Mw group (3.1% vs 46.8%. protective efficacy - 93.33%, p=0.0001; 95% CI 53.3-99.1). Self-limiting local injection site reaction was the only side effect and was seen in 14 HCW. Findings from the study suggest the potential for providing resistance against novel pathogen like SARS-CoV-2 by modulating innate immune response.
Competing Interest Statement
Bakulesh Khamar (one of the co-author) helped in designing of the study. He is employed as the Executive Director, Research in Cadila Pharmaceuticals Ltd. Cadila Pharmaceuticals Ltd is manufacturer of Sepsivac used in the study. Rest of the authors have no conflicts of interest to disclose.
Clinical Trial
CTRI/2020/10/028326
Funding Statement
No external funding received. Cadila Pharmaceuticals Ltd provided Sepsivac free for the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Ethics Committee meeting(EC) of Dharamshila Narayana Superspeciality Hospital(DNSH), provided approval. The meeting was held on 18.05.2020 online.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authorship Contribution: SRJ, BK and SC designed the study. AM, RL, GB and HM performed the study. SRJ, AM, GB and HM collected the data. SRJ and SC analyzed the data; SRJ and SC wrote the manuscript. All the co-authors reviewed and approved the manuscript.
Financial disclosure: BK is currently employed as the Executive Director, Research in Cadila Pharmaceuticals Ltd. Rest of the authors have no conflicts of interest to disclose.
Funding: Cadila Pharmaceuticals Ltd provided MIP vaccine (Sepsivac) for the study.
Data Availability
Available on request.
